
Limited Role for ICI Rechallenge in RCC Spurs Interest in More Tailored Later-Line Strategies
Despite the lack of clinical benefit generated by immune checkpoint inhibitor (ICI) rechallenge for most patients with advanced renal cell carcinoma (RCC) who have progressed on prior immunotherapy, ongoing research is seeking to clarify the application of …